1-6 of 6
Elise C. Kohn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C124: Proteomic and phenotype derived model for selection of combinations of targeted therapies in ovarian cancer.

Free
John L. Hays, Eric C. Polley, Jason J. David, Joyce Lu, Anna M. Leone, Saawan Mehta, Elise C. Kohn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C124.
https://doi.org/10.1158/1535-7163.TARG-13-C124
Published: 01 November 2013
View articletitled, Abstract C124: Proteomic and phenotype derived model for selection of combinations of targeted therapies in ovarian cancer.
Journal Articles

Abstract A249: Navitoclax and veliparib yield cytotoxicity with lower doses than used for single agents in women's cancers.

Free
Jung-Min Lee, Alyssa Stacy, Minshu Yu, Elise C. Kohn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A249.
https://doi.org/10.1158/1535-7163.TARG-13-A249
Published: 01 November 2013
View articletitled, Abstract A249: Navitoclax and veliparib yield cytotoxicity with lower doses than used for single agents in women's cancers.
Journal Articles

Abstract C158: IKKβ inhibition modulates NF‐κB signaling and decreases aggressiveness of ovarian cancer

Free
Lidia Hernandez, Sarah Hsu, Ben Davidson, Michael J. Birrer, Elise C. Kohn, Christina M. Annunziata
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C158.
https://doi.org/10.1158/1535-7163.TARG-09-C158
Published: 10 December 2009
View articletitled, Abstract C158: IKKβ inhibition modulates NF‐κB signaling and decreases aggressiveness of ovarian cancer
Journal Articles

Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines

Free
Philip L. Lorenzi, Jenny Llamas, Michele Gunsior, Laurent Ozbun, William C. Reinhold, Sudhir Varma, Helen Ji, Hijoo Kim, Amy A. Hutchinson, Elise C. Kohn, Paul K. Goldsmith, Michael J. Birrer, John N. Weinstein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (10): 3123–3128.
https://doi.org/10.1158/1535-7163.MCT-08-0589
Published: 13 October 2008
View articletitled, Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines
Open the PDF for Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines in another window
Includes: Supplementary data
Journal Articles

Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers

Free
Ellen V. Stevens, Satoshi Nishizuka, Smitha Antony, Mark Reimers, Sudhir Varma, Lynn Young, Peter J. Munson, John N. Weinstein, Elise C. Kohn, Yves Pommier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 10–18.
https://doi.org/10.1158/1535-7163.MCT-07-0192
Published: 17 January 2008
View articletitled, Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers
Open the PDF for Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers in another window
Journal Articles

Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells

Free
Philip L. Lorenzi, William C. Reinhold, Martina Rudelius, Michele Gunsior, Uma Shankavaram, Kimberly J. Bussey, Uwe Scherf, Gabriel S. Eichler, Scott E. Martin, Koei Chin, Joe W. Gray, Elise C. Kohn, Ivan D. Horak, Daniel D. Von Hoff, Mark Raffeld, Paul K. Goldsmith, Natasha J. Caplen, John N. Weinstein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (11): 2613–2623.
https://doi.org/10.1158/1535-7163.MCT-06-0447
Published: 22 November 2006
View articletitled, Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells
Open the PDF for Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells in another window